{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:35:02Z","timestamp":1783740902394,"version":"3.55.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Biologic disease modifying antirheumatic drugs (bDMARDs) and Janus Kinase (JAK) inhibitors are prescribed in adult and paediatric rheumatology. Due to age-dependent changes, disease course, and pharmacokinetic processes paediatric patients with inflammatory rheumatic diseases (PiRD) differ from adult rheumatology patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic literature search for randomized clinical trials (RCTs) in PiRD treated with bDMARDs\/JAK inhibitors was conducted on Medline,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link>, clinicaltrialsregister.eu and conference abstracts as of July 2020. RCTs were included if (i) patients were aged \u226420\u2009years, (ii) patients had a predefined rheumatic diagnosis and (iii) RCT reported predefined outcomes. Selected studies were excluded in case of (i) observational or single arm study or (ii) sample size \u22645 patients. Study characteristics were extracted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of 608 screened references, 65 references were selected, reporting 35 unique RCTs. All 35 RCTs reported efficacy while 34\/35 provided safety outcomes and 16\/35 provided pharmacokinetic data. The most common investigated treatments were TNF inhibitors (60%), IL-1 inhibitors (17%) and IL-6 inhibitors (9%). No RCTs with published results were identified for baricitinib, brodalumab, certolizumab pegol, guselkumab, risankizumab, rituximab, sarilumab, secukinumab, tildrakizumab, or upadacitinib. In patients with juvenile idiopathic arthritis (JIA) 25\/35 RCTs were conducted. The remaining 10 RCTs were performed in non-JIA patients including plaque psoriasis, Kawasaki Disease, systemic lupus erythematosus and non-infectious uveitis. In JIA-RCTs, the control arm was mainly placebo and the concomitant treatments were either methotrexate, non-steroidal anti-inflammatory drugs (NSAID) or corticosteroids. Non-JIA patients mostly received NSAID. There are ongoing trials investigating abatacept, adalimumab, baricitinib, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, risankizumab, secukinumab, tofacitinib and tildrakizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite the FDA Modernization Act and support of major paediatric rheumatology networks, such as the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organization (PRINTO), which resulted in drug approval for PiRD indications, there are limited RCTs in PiRD patients. As therapy response is influenced by age-dependent changes, pharmacokinetic processes and disease course it is important to consider developmental changes in bDMARDs\/JAK inhibitor use in PiRD patients. As such it is critical to collaborate and conduct international RCTs to appropriately investigate and characterize efficacy, safety and pharmacokinetics of bDMARDs\/JAK inhibitors in paediatric rheumatology.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12969-021-00514-4","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T21:02:54Z","timestamp":1616706174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology \u2013 what we know and what we do not know from randomized controlled trials"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1800-0327","authenticated-orcid":false,"given":"Tatjana","family":"Welzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Winskill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Woerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"issue":"9","key":"514_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/01.NPR.0000520831.76287.56","volume":"42","author":"M Teague","year":"2017","unstructured":"Teague M. Pediatric rheumatologic diseases: a review for primary care NPs. Nurse Pract. 2017;42(9):43\u20137.","journal-title":"Nurse Pract"},{"issue":"2","key":"514_CR2","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"9563","key":"514_CR3","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767\u201378.","journal-title":"Lancet."},{"issue":"5","key":"514_CR4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/01.bor.0000130286.54383.ea","volume":"16","author":"N Ruperto","year":"2004","unstructured":"Ruperto N, Martini A. International research networks in pediatric rheumatology: the PRINTO perspective. Curr Opin Rheumatol. 2004;16(5):566\u201370.","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"514_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/rheumatology\/38.2.176","volume":"38","author":"N Ruperto","year":"1999","unstructured":"Ruperto N, Ravelli A, Falcini F, Lepore L, Buoncompagni A, Gerloni V, et al. Responsiveness of outcome measures in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. Rheumatology. 1999;38(2):176\u201380.","journal-title":"Rheumatology"},{"issue":"1","key":"514_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12969-016-0085-5","volume":"14","author":"A Consolaro","year":"2016","unstructured":"Consolaro A, Giancane G, Schiappapietra B, Davi S, Calandra S, Lanni S, et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2016;14(1):23.","journal-title":"Pediatr Rheumatol Online J."},{"issue":"5","key":"514_CR7","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658\u201366.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"514_CR8","first-page":"819","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819\u201328.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"514_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12969-018-0257-6","volume":"16","author":"CH Hinze","year":"2018","unstructured":"Hinze CH, Oommen PT, Dressler F, Urban A, Weller-Heinemann F, Speth F, et al. Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria. Pediatr Rheumatol Online J. 2018;16(1):40.","journal-title":"Pediatr Rheumatol Online J."},{"issue":"1","key":"514_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12969-020-0409-3","volume":"18","author":"S Hansmann","year":"2020","unstructured":"Hansmann S, Lainka E, Horneff G, Holzinger D, Rieber N, Jansson AF, et al. Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD\/HIDS: a German PRO-KIND initiative. Pediatr Rheumatol Online J. 2020;18(1):17.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4 Suppl 73","key":"514_CR11","first-page":"S2","volume":"30","author":"JS Smolen","year":"2012","unstructured":"Smolen JS. Treat-to-target: rationale and strategies. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S2\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"514_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.trsl.2015.06.006","volume":"167","author":"SS McCoy","year":"2016","unstructured":"McCoy SS, Stannard J, Kahlenberg JM. Targeting the inflammasome in rheumatic diseases. Transl Res. 2016;167(1):125\u201337.","journal-title":"Transl Res"},{"issue":"5","key":"514_CR13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2352-4642(18)30034-8","volume":"2","author":"N Ruperto","year":"2018","unstructured":"Ruperto N, Martini A. Current and future perspectives in the management of juvenile idiopathic arthritis. Lancet Child Adolesc Health. 2018;2(5):360\u201370.","journal-title":"Lancet Child Adolesc Health"},{"key":"514_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fimmu.2019.00450","volume":"10","author":"L Maggi","year":"2019","unstructured":"Maggi L, Mazzoni A, Cimaz R, Liotta F, Annunziato F, Cosmi L. Th17 and Th1 lymphocytes in Oligoarticular juvenile idiopathic arthritis. Front Immunol. 2019;10:450.","journal-title":"Front Immunol"},{"key":"514_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-med-061512-150641","volume":"65","author":"AA Jesus","year":"2014","unstructured":"Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Annu Rev Med. 2014;65:223\u201344.","journal-title":"Annu Rev Med"},{"issue":"9","key":"514_CR16","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00431-017-2960-6","volume":"176","author":"F Vanoni","year":"2017","unstructured":"Vanoni F, Minoia F, Malattia C. Biologics in juvenile idiopathic arthritis: a narrative review. Eur J Pediatr. 2017;176(9):1147\u201353.","journal-title":"Eur J Pediatr"},{"issue":"7","key":"514_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11926-016-0593-9","volume":"18","author":"Y Sterba","year":"2016","unstructured":"Sterba Y, Ilowite N. Biologics in pediatric rheumatology: quo Vadis? Curr Rheumatol Rep. 2016;18(7):45.","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"514_CR18","doi-asserted-by":"publisher","first-page":"rkz004","DOI":"10.1093\/rap\/rkz004","volume":"3","author":"S Garg","year":"2019","unstructured":"Garg S, Wynne K, Omoyinmi E, Eleftheriou D, Brogan P. Efficacy and safety of anakinra for undifferentiated autoinflammatory diseases in children: a retrospective case review. Rheumatol Adv Pract. 2019;3(1):rkz004.","journal-title":"Rheumatol Adv Pract"},{"issue":"1","key":"514_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12969-018-0261-x","volume":"16","author":"HI Brunner","year":"2018","unstructured":"Brunner HI, Rider LG, Kingsbury DJ, Co D, Schneider R, Goldmuntz E, et al. Pediatric rheumatology collaborative study group - over four decades of pivotal clinical drug research in pediatric rheumatology. Pediatr Rheumatol Online J. 2018;16(1):45.","journal-title":"Pediatr Rheumatol Online J."},{"issue":"1","key":"514_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12969-018-0296-z","volume":"16","author":"JY Jung","year":"2018","unstructured":"Jung JY, Kim MY, Suh CH, Kim HA. Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review. Pediatr Rheumatol Online J. 2018;16(1):79.","journal-title":"Pediatr Rheumatol Online J."},{"key":"514_CR21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fphar.2016.00380","volume":"7","author":"A Vitale","year":"2016","unstructured":"Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M, et al. A snapshot on the on-label and off-label use of the Interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a Nationwide multi-center retrospective observational study. Front Pharmacol. 2016;7:380.","journal-title":"Front Pharmacol"},{"issue":"7","key":"514_CR22","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","volume":"128","author":"GAM Sanchez","year":"2018","unstructured":"Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041\u201352.","journal-title":"J Clin Invest"},{"issue":"4","key":"514_CR23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s13555-018-0269-7","volume":"8","author":"F Gomez-Garcia","year":"2018","unstructured":"Gomez-Garcia F, Sanz-Cabanillas JL, Viguera-Guerra I, Isla-Tejera B, Nieto AV, Ruano J. Scoping review on use of drugs targeting interleukin 1 pathway in DIRA and DITRA. Dermatol Ther (Heidelb). 2018;8(4):539\u201356.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"514_CR24","doi-asserted-by":"publisher","first-page":"P338","DOI":"10.1186\/1546-0096-12-S1-P338","volume":"12","author":"A Woerner","year":"2014","unstructured":"Woerner A, Belot A, Merlin E, Wouters C, Berthet G, Kondi A, et al. Prescribed but not approved: biologic agents used without approval in juvenile idiopathic arthritis in Switzerland, France and Belgium. Pediatr Rheumatol. 2014;12(1):P338.","journal-title":"Pediatr Rheumatol"},{"issue":"1","key":"514_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12969-019-0322-9","volume":"17","author":"M Boyadzhiev","year":"2019","unstructured":"Boyadzhiev M, Marinov L, Boyadzhiev V, Iotova V, Aksentijevich I, Hambleton S. Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome. Pediatr Rheumatol Online J. 2019;17(1):19.","journal-title":"Pediatr Rheumatol Online J."},{"issue":"1","key":"514_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/art.24174","volume":"60","author":"P Picco","year":"2009","unstructured":"Picco P, Brisca G, Traverso F, Loy A, Gattorno M, Martini A. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum. 2009;60(1):264\u20138.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"514_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.berh.2018.09.007","volume":"32","author":"S Ozen","year":"2018","unstructured":"Ozen S, Sonmez HE, Demir S. Pediatric forms of vasculitis. Best Pract Res Clin Rheumatol. 2018;32(1):137\u201347.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"514_CR28","unstructured":"Lei C, Huang Y, Yuan S, Chen W, Liu H, Yang M, et al. Takayasu Arteritis With Coronary Artery Involvement: Differences Between Pediatric and Adult Patients. Can J Cardiol. 2019."},{"issue":"12","key":"514_CR29","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1002\/art.38853","volume":"66","author":"D Condie","year":"2014","unstructured":"Condie D, Grabell D, Jacobe H. Comparison of outcomes in adults with pediatric-onset morphea and those with adult-onset morphea: a cross-sectional study from the morphea in adults and children cohort. Arthritis Rheumatol. 2014;66(12):3496\u2013504.","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"514_CR30","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1177\/0961203314563817","volume":"24","author":"T Tarr","year":"2015","unstructured":"Tarr T, Derfalvi B, Gyori N, Szanto A, Siminszky Z, Malik A, et al. Similarities and differences between pediatric and adult patients with systemic lupus erythematosus. Lupus. 2015;24(8):796\u2013803.","journal-title":"Lupus."},{"issue":"3","key":"514_CR31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.reuma.2016.10.011","volume":"14","author":"R Fonseca","year":"2018","unstructured":"Fonseca R, Aguiar F, Rodrigues M, Brito I. Clinical phenotype and outcome in lupus according to age: a comparison between juvenile and adult onset. Reumatol Clin. 2018;14(3):160\u20133.","journal-title":"Reumatol Clin"},{"issue":"12","key":"514_CR32","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1002\/art.40577","volume":"70","author":"S Panupattanapong","year":"2018","unstructured":"Panupattanapong S, Stwalley DL, White AJ, Olsen MA, French AR, Hartman ME. Epidemiology and outcomes of Granulomatosis with Polyangiitis in pediatric and working-age adult populations in the United States: analysis of a large National Claims Database. Arthritis Rheumatol. 2018;70(12):2067\u201376.","journal-title":"Arthritis Rheumatol"},{"issue":"22","key":"514_CR33","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1136\/heartjnl-2017-311774","volume":"103","author":"KJ Denby","year":"2017","unstructured":"Denby KJ, Clark DE, Markham LW. Management of Kawasaki disease in adults. Heart. 2017;103(22):1760\u20139.","journal-title":"Heart."},{"issue":"2","key":"514_CR34","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/BOR.0b013e32835d8e2a","volume":"25","author":"M Piram","year":"2013","unstructured":"Piram M, Mahr A. Epidemiology of immunoglobulin a vasculitis (Henoch-Schonlein): current state of knowledge. Curr Opin Rheumatol. 2013;25(2):171\u20138.","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"514_CR35","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/rheumatology\/key058","volume":"57","author":"H Girschick","year":"2018","unstructured":"Girschick H, Finetti M, Orlando F, Schalm S, Insalaco A, Ganser G, et al. The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. Rheumatology. 2018;57(7):1203\u201311.","journal-title":"Rheumatology."},{"issue":"2","key":"514_CR36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10067-016-3317-7","volume":"36","author":"D Rigante","year":"2017","unstructured":"Rigante D, Vitale A, Natale MF, Lopalco G, Andreozzi L, Frediani B, et al. A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome. Clin Rheumatol. 2017;36(2):463\u20138.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"514_CR37","first-page":"1107","volume":"77","author":"T Constantin","year":"2018","unstructured":"Constantin T, Foeldvari I, Anton J, de Boer J, Czitrom-Guillaume S, Edelsten C, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018;77(8):1107\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"514_CR38","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","volume":"135","author":"BW McCrindle","year":"2017","unstructured":"McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term Management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927\u2013e99.","journal-title":"Circulation."},{"issue":"4","key":"514_CR39","doi-asserted-by":"publisher","first-page":"e1043","DOI":"10.1097\/01.mjt.0000489921.28180.b9","volume":"23","author":"I Mahmood","year":"2016","unstructured":"Mahmood I. Pharmacokinetic considerations in designing pediatric studies of proteins, antibodies, and plasma-derived products. Am J Ther. 2016;23(4):e1043\u201356.","journal-title":"Am J Ther"},{"issue":"Suppl 10","key":"514_CR40","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1002\/jcph.1284","volume":"58","author":"J van den Anker","year":"2018","unstructured":"van den Anker J, Reed MD, Allegaert K, Kearns GL. Developmental changes in pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2018;58(Suppl 10):S10\u201325.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"514_CR41","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157\u201367.","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"514_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ijpharm.2015.05.012","volume":"492","author":"J Samardzic","year":"2015","unstructured":"Samardzic J, Allegaert K, Bajcetic M. Developmental pharmacology: a moving target. Int J Pharm. 2015;492(1\u20132):335\u20137.","journal-title":"Int J Pharm"},{"issue":"1","key":"514_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.40350","volume":"70","author":"PA Nigrovic","year":"2018","unstructured":"Nigrovic PA, Raychaudhuri S, Thompson SD. Review: genetics and the classification of arthritis in adults and children. Arthritis Rheumatol. 2018;70(1):7\u201317.","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"514_CR44","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/17425255.2018.1482278","volume":"14","author":"P Malik","year":"2018","unstructured":"Malik P, Edginton A. Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. Expert Opin Drug Metab Toxicol. 2018;14(6):585\u201399.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"9128","key":"514_CR45","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0140-6736(05)79591-X","volume":"352","author":"P Moore","year":"1998","unstructured":"Moore P. Children are not small adults. Lancet. 1998;352(9128):630.","journal-title":"Lancet"},{"issue":"S 01","key":"514_CR46","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1055\/a-0731-6913","volume":"68","author":"K Allegaert","year":"2018","unstructured":"Allegaert K. Developmental Pharmacology - Special Issues During Childhood and Adolescence. Drug Res (Stuttg). 2018;68(S 01):S10\u2013S1.","journal-title":"Drug Res (Stuttg)"},{"issue":"2","key":"514_CR47","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/rheumatology\/kez441","volume":"59","author":"WD Renton","year":"2020","unstructured":"Renton WD, Ramanan AV. Better pharmacologic data the key to optimizing biological therapies in children. Rheumatology. 2020;59(2):271\u20132.","journal-title":"Rheumatology."},{"issue":"9636","key":"514_CR48","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383\u201391.","journal-title":"Lancet."},{"issue":"11","key":"514_CR49","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1002\/acr.20283","volume":"62","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Li T, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res. 2010;62(11):1542\u201351.","journal-title":"Arthritis Care Res"},{"issue":"6","key":"514_CR50","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/art.27431","volume":"62","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(6):1792\u2013802.","journal-title":"Arthritis Rheum"},{"key":"514_CR51","unstructured":"Ruperto N, Lovell D, Bohnsack J, Breedt J, Fischbach M, Lutz T, et al. Subcutaneous or IntravenousAbatacept Monotherapy in Pediatric Patients with Polyarticular-Course JIA: Results from Two Phase III Trials [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https:\/\/acrabstracts.org\/abstract\/subcutaneous-or-intravenous-abatacept-monotherapy-in-pediatric-patients-with-polyarticular-course-jia-results-from-two-phase-iii-trials\/. Accessed 23 Mar 2020."},{"issue":"2","key":"514_CR52","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","volume":"28","author":"N Ilowite","year":"2009","unstructured":"Ilowite N, Porras O, Reiff A, Rudge S, Punaro M, Martin A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol. 2009;28(2):129\u201337.","journal-title":"Clin Rheumatol"},{"key":"514_CR53","volume-title":"CHMP extension of indication variation assessment report (anakinra)","author":"European Medicines Agency","year":"2018","unstructured":"European Medicines Agency. CHMP extension of indication variation assessment report (anakinra), 2018. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/kineret-h-c-363-ii-0056-epar-assessment-report-variation_en.pdf. (23 March 2020, date last accessed)"},{"issue":"5","key":"514_CR54","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747\u201354.","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"514_CR55","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396\u2013406.","journal-title":"N Engl J Med"},{"key":"514_CR56","volume-title":"Medical review and evaluation (canakinumab)","author":"US Food","year":"2016","unstructured":"US Food and Drug Administration. Medical review and evaluation (canakinumab), 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/125319Orig1s085,086,087MedR.pdf. (23 March 2020, date last accessed)."},{"key":"514_CR57","volume-title":"Summary of product characteristics (canakinumab)","author":"European Medicines Agency","year":"2014","unstructured":"European Medicines Agency. Summary of product characteristics (canakinumab), 2014. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ilaris-epar-product-information_en.pdf. (23 March 2020, date last accessed)"},{"key":"514_CR58","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT00534495, Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults; 2007 Sept 26 [cited 2020 July 15]; [about 14 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00534495"},{"issue":"9","key":"514_CR59","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/art.38699","volume":"66","author":"NT Ilowite","year":"2014","unstructured":"Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, et al. Randomized, double blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66(9):2570\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"514_CR60","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/art.38042","volume":"65","author":"DJ Lovell","year":"2013","unstructured":"Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65(9):2486\u201396.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"514_CR61","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","volume":"74","author":"HI Brunner","year":"2015","unstructured":"Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74(6):1110\u20137.","journal-title":"Ann Rheum Dis"},{"key":"514_CR62","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT00988221, A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis; 2009 Oct 2 [cited 2020 July 15]; [about 50 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00988221"},{"key":"514_CR63","unstructured":"Brunner H, Chen C, Martini A, Espada G, Joos R, Akikusa J, et al. Disability and Health-Related Quality of Life Outcomes in Patients with Systemic or Polyarticular Juvenile Idiopathic Arthritis Treated with Tocilizumab in Randomized Controlled Phase 3 Trials [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https:\/\/acrabstracts.org\/abstract\/disability-and-health-related-quality-of-life-outcomes-in-patients-with-systemic-or-polyarticular-juvenile-idiopathic-arthritis-treated-with-tocilizumab-in-randomized-controlled-phase-3-trials\/. Accessed 23 Mar 2020."},{"key":"514_CR64","unstructured":"US Food and Drug Administration. Medical review and evaluation (tocilizumab), 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/125276Orig1s064.pdf. (23 March 2020, date last accessed)"},{"key":"514_CR65","unstructured":"European Medicines Agency. Assessment report (tocilizumab), 2013. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/roactemra-h-c-955-ii-0026-epar-assessment-report-variation_en.pdf (23 March 2020, date last accessed)."},{"issue":"25","key":"514_CR66","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395.","journal-title":"N Engl J Med"},{"key":"514_CR67","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT00642460, A Study of RoActemra\/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA); 2008 Mar 25 [cited 2020 July 15]; [about 64 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00642460"},{"issue":"9617","key":"514_CR68","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998\u20131006.","journal-title":"Lancet."},{"issue":"11","key":"514_CR69","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/acr.22657","volume":"67","author":"R Burgos-Vargas","year":"2015","unstructured":"Burgos-Vargas R, Tse SM, Horneff G, Pangan AL, Kalabic J, Goss S, et al. A randomized, double blind, placebo-controlled multicenter study of Adalimumab in pediatric patients with Enthesitis-related arthritis. Arthritis Care Res. 2015;67(11):1503\u201312.","journal-title":"Arthritis Care Res."},{"key":"514_CR70","volume-title":"Assessment report for paediatric studies submitted according to Article 46 of the Regulation (EC) No 1901\/2006 (adalimumab)","author":"European Medicines Agency","year":"2016","unstructured":"European Medicines Agency. Assessment report for paediatric studies submitted according to Article 46 of the Regulation (EC) No 1901\/2006 (adalimumab), 2016. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/humira-h-c-481-p46-0093-epar-assessment-report_en.pdf (23 March 2020, date last accessed)."},{"key":"514_CR71","volume-title":"CHMP extension of indication variation assessment report (adalimumab)","author":"European Medicines Agency","year":"2014","unstructured":"European Medicines Agency. CHMP extension of indication variation assessment report (adalimumab), 2014. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/humira-h-c-481-ii-00127-epar-assessment-report-variation_en.pdf (23 March 2020, date last accessed)."},{"issue":"5","key":"514_CR72","doi-asserted-by":"publisher","first-page":"R230","DOI":"10.1186\/ar4072","volume":"14","author":"G Horneff","year":"2012","unstructured":"Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle-Deschner J, Tzaribacev N, et al. Double blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther. 2012;14(5):R230.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"514_CR73","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810\u201320.","journal-title":"N Engl J Med"},{"key":"514_CR74","volume-title":"Assessment report (adalimumab)","author":"European Medicines Agency","year":"2011","unstructured":"European Medicines Agency. Assessment report (adalimumab), 2011. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/humira-h-c-481-ii-0081-g-epar-assessment-report-variation_en.pdf (23 March 2020, date last accessed)."},{"issue":"17","key":"514_CR75","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","volume":"376","author":"AV Ramanan","year":"2017","unstructured":"Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637\u201346.","journal-title":"N Engl J Med"},{"key":"514_CR76","volume-title":"Assessment report (adalimumab)","author":"European Medicines Agency","year":"2017","unstructured":"European Medicines Agency. Assessment report (adalimumab), 2017. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/humira-h-c-481-ii-0163-epar-assessment-report-variation_en.pdf (23 March 2020, date last accessed)."},{"issue":"7","key":"514_CR77","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","volume":"77","author":"P Quartier","year":"2018","unstructured":"Quartier P, Baptiste A, Despert V, Allain-Launay E, Kone-Paut I, Belot A, et al. ADJUVITE: a double blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018;77(7):1003\u201311.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"514_CR78","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1002\/art.39145","volume":"67","author":"G Horneff","year":"2015","unstructured":"Horneff G, Foeldvari I, Minden K, Trauzeddel R, Kummerle-Deschner JB, Tenbrock K, et al. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study. Arthritis Rheumatol. 2015;67(8):2240\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"514_CR79","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group. N Engl J Med. 2000;342(11):763\u20139.","journal-title":"N Engl J Med"},{"key":"514_CR80","volume-title":"Medical review and evaluation (etanercept)","author":"US Food and Drug Administration","year":"1999","unstructured":"US Food and Drug Administration. Medical review and evaluation (etanercept), 1999. https:\/\/web.archive.org\/web\/20161024172432\/http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/ucm088846.pdf (23 March 2020, date last accessed)."},{"key":"514_CR81","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT03780959, Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA); 2018 Dec 19 [cited 2020 July 15]; [about 12 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03780959"},{"key":"514_CR82","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT03781375, Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis; 2018 Dec 19 [cited 2020 July 15]; [about 13 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03781375"},{"issue":"6","key":"514_CR83","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/art.34343","volume":"64","author":"CA Wallace","year":"2012","unstructured":"Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(6):2012\u201321.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"514_CR84","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3899\/jrheum.131503","volume":"41","author":"CA Wallace","year":"2014","unstructured":"Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, et al. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol. 2014;41(6):1163\u201370.","journal-title":"J Rheumatol"},{"key":"514_CR85","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT00078806, Safety and Efficacy Study of Etanercept (Enbrel\u00ae) In Children With Systemic Onset Juvenile Rheumatoid Arthritis; 2004 Mar 9 [cited 2020 July 15]; [about 24 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00078806"},{"issue":"1","key":"514_CR86","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12969-017-0138-4","volume":"15","author":"PC Hissink Muller","year":"2017","unstructured":"Hissink Muller PC, Brinkman DM, Schonenberg D, Koopman-Keemink Y, Brederije IC, Bekkering WP, et al. A comparison of three treatment strategies in recent onset non-systemic juvenile idiopathic arthritis: initial 3-months results of the BeSt for Kids-study. Pediatr Rheumatol Online J. 2017;15(1):11.","journal-title":"Pediatr Rheumatol Online J."},{"issue":"1","key":"514_CR87","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2018-213902","volume":"78","author":"P Hissink Muller","year":"2019","unstructured":"Hissink Muller P, Brinkman DMC, Schonenberg-Meinema D, van den Bosch WB, Koopman-Keemink Y, Brederije ICJ, et al. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. Ann Rheum Dis. 2019;78(1):51\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"514_CR88","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","volume":"77","author":"HI Brunner","year":"2018","unstructured":"Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2018;77(1):21\u20139.","journal-title":"Ann Rheum Dis"},{"key":"514_CR89","volume-title":"Assessment report (golimumab)","author":"European Medicines Agency","year":"2016","unstructured":"European Medicines Agency. Assessment report (golimumab), 2016. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/simponi-h-c-992-ii-0063-epar-assessment-report-variation_en.pdf (23 March 2020, date last accessed)."},{"issue":"9","key":"514_CR90","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096\u2013106.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"514_CR91","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/ard.2010.143347","volume":"70","author":"P Tynjala","year":"2011","unstructured":"Tynjala P, Vahasalo P, Tarkiainen M, Kroger L, Aalto K, Malin M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70(9):1605\u201312.","journal-title":"Ann Rheum Dis"},{"key":"514_CR92","unstructured":"Brunner H, Synoverska O, Ting T, Abud Mendoza C, Spindler A, Vyzhga Y, et al. Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study [abstract]. Arthritis Rheumatol. 2019;71(suppl 10) https:\/\/acrabstracts.org\/abstract\/tofacitinib-for-the-treatment-of-polyarticular-course-juvenile-idiopathic-arthritis-results-of-a-phase-3-randomized-double-blind-placebo-controlled-withdrawal-study\/. Accessed 23 Mar 2020."},{"issue":"4","key":"514_CR93","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","volume":"73","author":"I Landells","year":"2015","unstructured":"Landells I, Marano C, Hsu MC, Li S, Zhu Y, Eichenfield LF, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594\u2013603.","journal-title":"J Am Acad Dermatol"},{"key":"514_CR94","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT03073200, Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis (Ixora-peds); 2017 Mar 08 [cited 2020 July 15]; [about 32 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03073200"},{"issue":"10089","key":"514_CR95","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","volume":"390","author":"K Papp","year":"2017","unstructured":"Papp K, Thaci D, Marcoux D, Weibel L, Philipp S, Ghislain PD, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10089):40\u20139.","journal-title":"Lancet."},{"key":"514_CR96","volume-title":"Assessment report for paediatric studies submitted according to Article 46 of the Regulation (EC) No 1901\/2006 (adalimumab)","author":"European Medicines Agency","year":"2015","unstructured":"European Medicines Agency. Assessment report for paediatric studies submitted according to Article 46 of the Regulation (EC) No 1901\/2006 (adalimumab), 2015. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/humira-h-c-481-p46-0088-epar-assessment-report_en.pdf (23 March 2020, date last accessed)."},{"key":"514_CR97","volume-title":"Extension of indication variation assessment report (adalimumab)","author":"European Medicines Agency","year":"2015","unstructured":"European Medicines Agency. Extension of indication variation assessment report (adalimumab), 2015. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/humira-h-c-481-ii-0134-epar-assessment-report-extension_en.pdf (23 March 2020, date last accessed)."},{"key":"514_CR98","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT01251614, A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate); 2010 Dec 2 [cited 2020 July 15]; [about 48 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01251614"},{"key":"514_CR99","doi-asserted-by":"crossref","unstructured":"Portman MA, Dahdah NS, Slee A, Olson AK, Choueiter NF, Soriano BD, et al. Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial. Pediatrics. 2019;143(6).","DOI":"10.1542\/peds.2018-3675"},{"issue":"3","key":"514_CR100","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa066886","volume":"358","author":"AS Paller","year":"2008","unstructured":"Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358(3):241\u201351.","journal-title":"N Engl J Med"},{"issue":"1","key":"514_CR101","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jaad.2010.02.060","volume":"64","author":"RG Langley","year":"2011","unstructured":"Langley RG, Paller AS, Hebert AA, Creamer K, Weng HH, Jahreis A, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol. 2011;64(1):64\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"514_CR102","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jaad.2009.10.046","volume":"63","author":"EC Siegfried","year":"2010","unstructured":"Siegfried EC, Eichenfield LF, Paller AS, Pariser D, Creamer K, Kricorian G. Intermittent etanercept therapy in pediatric patients with psoriasis. J Am Acad Dermatol. 2010;63(5):769\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"514_CR103","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1684\/ejd.2010.0911","volume":"20","author":"I Landells","year":"2010","unstructured":"Landells I, Paller AS, Pariser D, Kricorian G, Foehl J, Molta C, et al. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis. Eur J Dermatol. 2010;20(3):323\u20138.","journal-title":"Eur J Dermatol"},{"key":"514_CR104","volume-title":"Assessment report (etanercept)","author":"European Medicines Agency","year":"2008","unstructured":"European Medicines Agency. Assessment report (etanercept), 2008. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/enbrel-h-c-262-ii-94-epar-assessment-report-variation_en.pdf (23 March 2020, date last accessed)."},{"key":"514_CR105","doi-asserted-by":"publisher","first-page":"7264","DOI":"10.12659\/MSM.908678","volume":"24","author":"CL Han","year":"2018","unstructured":"Han CL, Zhao SL. Intravenous immunoglobulin gamma (IVIG) versus IVIG plus infliximab in young children with Kawasaki disease. Med Sci Monit. 2018;24:7264\u201370.","journal-title":"Med Sci Monit"},{"issue":"1","key":"514_CR106","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41598-017-18387-7","volume":"8","author":"M Mori","year":"2018","unstructured":"Mori M, Hara T, Kikuchi M, Shimizu H, Miyamoto T, Iwashima S, et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Sci Rep. 2018;8(1):1994.","journal-title":"Sci Rep"},{"issue":"9930","key":"514_CR107","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(13)62298-9","volume":"383","author":"AH Tremoulet","year":"2014","unstructured":"Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9930):1731\u20138.","journal-title":"Lancet."},{"issue":"12","key":"514_CR108","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/INF.0000000000000891","volume":"34","author":"P Jaggi","year":"2015","unstructured":"Jaggi P, Wang W, Dvorchik I, Printz B, Berry E, Kovalchin JP, et al. Patterns of fever in children after primary treatment for Kawasaki disease. Pediatr Infect Dis J. 2015;34(12):1315\u20138.","journal-title":"Pediatr Infect Dis J"},{"key":"514_CR109","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT00589628, Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis; 2008 Jan 10 [cited 2020 July 15]; [about 7 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00589628"},{"key":"514_CR110","doi-asserted-by":"crossref","unstructured":"Nino A, Bass D, Eriksson G, Hammer A, Ji B, Quasny H, Roth D. Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: An Across-Trial Comparison with the Adult Belimumab Studies [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-intravenous-belimumab-in-children-with-systemic-lupus-erythematosus-an-across-trial-comparison-with-the-adult-belimumab-studies\/. Accessed 23 Mar 2020.","DOI":"10.1136\/lupus-2020-eurolupus.172"},{"key":"514_CR111","volume-title":"Assessment report (belimumab)","author":"European Medicines Agency","year":"2019","unstructured":"European Medicines Agency. Assessment report (belimumab), 2019. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/benlysta-h-c-2015-ii-0062-epar-assessment-report-variation_en.pdf (23 March 2020, date last accessed)."},{"issue":"4","key":"514_CR112","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/aogs.13309","volume":"97","author":"A Bhide","year":"2018","unstructured":"Bhide A, Shah PS, Acharya G. A simplified guide to randomized controlled trials. Acta Obstet Gynecol Scand. 2018;97(4):380\u20137.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"6","key":"514_CR113","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1136\/adc.2010.188946","volume":"96","author":"N Ruperto","year":"2011","unstructured":"Ruperto N, Martini A. Networking in paediatrics: the example of the Paediatric rheumatology international trials organisation (PRINTO). Arch Dis Child. 2011;96(6):596\u2013601.","journal-title":"Arch Dis Child"},{"issue":"4","key":"514_CR114","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465\u201382.","journal-title":"Arthritis Care Res."},{"issue":"6","key":"514_CR115","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/acr.23871","volume":"71","author":"ST Angeles-Han","year":"2019","unstructured":"Angeles-Han ST, Ringold S, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology\/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res. 2019;71(6):703\u201316.","journal-title":"Arthritis Care Res."},{"issue":"2","key":"514_CR116","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.therap.2018.02.002","volume":"73","author":"F Moulis","year":"2018","unstructured":"Moulis F, Durrieu G, Lapeyre-Mestre M. Off-label and unlicensed drug use in children population. Therapie. 2018;73(2):135\u201349.","journal-title":"Therapie."},{"issue":"1","key":"514_CR117","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/1574884712666170317161935","volume":"12","author":"R Gore","year":"2017","unstructured":"Gore R, Chugh PK, Tripathi CD, Lhamo Y, Gautam S. Pediatric off-label and unlicensed drug use and its implications. Curr Clin Pharmacol. 2017;12(1):18\u201325.","journal-title":"Curr Clin Pharmacol"},{"issue":"3","key":"514_CR118","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1136\/adc.2010.191940","volume":"96","author":"S Conroy","year":"2011","unstructured":"Conroy S. Association between licence status and medication errors. Arch Dis Child. 2011;96(3):305\u20136.","journal-title":"Arch Dis Child"},{"issue":"46","key":"514_CR119","first-page":"781","volume":"112","author":"S Wimmer","year":"2015","unstructured":"Wimmer S, Neubert A, Rascher W. The safety of drug therapy in children. Dtsch Arztebl Int. 2015;112(46):781\u20137.","journal-title":"Dtsch Arztebl Int"},{"key":"514_CR120","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/1741-7015-11-238","volume":"11","author":"JR Bellis","year":"2013","unstructured":"Bellis JR, Kirkham JJ, Thiesen S, Conroy EJ, Bracken LE, Mannix HL, et al. Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital. BMC Med. 2013;11:238.","journal-title":"BMC Med"},{"issue":"2","key":"514_CR121","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/cpt.936","volume":"104","author":"H Kim","year":"2018","unstructured":"Kim H, Brooks KM, Tang CC, Wakim P, Blake M, Brooks SR, et al. Pharmacokinetics, pharmacodynamics, and proposed dosing of the Oral JAK1 and JAK2 inhibitor Baricitinib in pediatric and young adult CANDLE and SAVI patients. Clin Pharmacol Ther. 2018;104(2):364\u201373.","journal-title":"Clin Pharmacol Ther"},{"issue":"14","key":"514_CR122","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. Jama. 2011;305(14):1460\u20138.","journal-title":"Jama."},{"issue":"3","key":"514_CR123","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/archdischild-2018-315060","volume":"104","author":"A Skrabl-Baumgartner","year":"2019","unstructured":"Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, Schlagenhauf A, Jahnel J. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis. Arch Dis Child. 2019;104(3):246\u201350.","journal-title":"Arch Dis Child"},{"key":"514_CR124","first-page":"13","volume":"74","author":"I Nestorov","year":"2005","unstructured":"Nestorov I. Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl. 2005;74:13\u20138.","journal-title":"J Rheumatol Suppl"},{"issue":"1","key":"514_CR125","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.25057","volume":"62","author":"B Neven","year":"2010","unstructured":"Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease\/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62(1):258\u201367.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"514_CR126","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1136\/ard.2011.152728","volume":"70","author":"JB Kuemmerle-Deschner","year":"2011","unstructured":"Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70(12):2095\u2013102.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"514_CR127","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/rheumatology\/kev416","volume":"55","author":"JB Kuemmerle-Deschner","year":"2016","unstructured":"Kuemmerle-Deschner JB, Hofer F, Endres T, Kortus-Goetze B, Blank N, Weissbarth-Riedel E, et al. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. Rheumatology. 2016;55(4):689\u201396.","journal-title":"Rheumatology."},{"issue":"7","key":"514_CR128","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1001\/jama.290.7.905","volume":"290","author":"R Roberts","year":"2003","unstructured":"Roberts R, Rodriguez W, Murphy D, Crescenzi T. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. Jama. 2003;290(7):905\u201311.","journal-title":"Jama."},{"issue":"5","key":"514_CR129","doi-asserted-by":"publisher","first-page":"e1291","DOI":"10.1542\/peds.2010-2847","volume":"129","author":"T Shamliyan","year":"2012","unstructured":"Shamliyan T, Kane RL. Clinical research involving children: registration, completeness, and publication. Pediatrics. 2012;129(5):e1291\u2013300.","journal-title":"Pediatrics."},{"key":"514_CR130","doi-asserted-by":"crossref","unstructured":"Pica N, Bourgeois F. Discontinuation and Nonpublication of Randomized Clinical Trials Conducted in Children. Pediatrics. 2016;138(3).","DOI":"10.1542\/peds.2016-0223"}],"updated-by":[{"DOI":"10.1186\/s12969-021-00593-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000}}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00514-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-021-00514-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00514-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T13:21:49Z","timestamp":1671715309000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00514-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":130,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["514"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00514-4","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12969-021-00593-3","asserted-by":"object"}]},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"19 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12969-021-00593-3","URL":"https:\/\/doi.org\/10.1186\/s12969-021-00593-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}